A Phase 1 interventional study of AZD3355 and Esomeprazole in Gastroesophageal Reflux Disease, sponsored by AstraZeneca. Completed at 1 site in Sweden. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-12-03.
Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing lesogaberan in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. lesogaberan · Gastroesophageal Reflux.
Among the 10 studies testing lesogaberan in Gastroesophageal Reflux, this one is the 7th largest by enrollment, is one of 4 that started in 2008, is one of 4 in phase 1, and was the 2nd registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →None of the 10 studies testing lesogaberan in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 51 across the 10 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 2 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
89 studies in Gastroesophageal Reflux by AstraZeneca: none open now, none under way, none of them phase 3. Of 89 finished, 15 (17%) have results posted.
Among the 89 studies in Gastroesophageal Reflux by AstraZeneca, this one is the 47th largest by enrollment of the 52 interventional ones that give a count, is one of 16 that started in 2008, is one of 6 in phase 1, and was the 45th registered.
AstraZeneca’s Gastroesophageal Reflux studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing lesogaberan in Gastroesophageal Reflux, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 89 in Gastroesophageal Reflux:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate if AZD3355 and Nexium interact with each other or not, i.e. show the same or altered plasma concentration profiles when co-administered compared to administered alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AZD3355 150 mg
Drug: AZD3355
Esomeprazole 40mg
Drug: Esomeprazole
AZD3355 150mg/Esomeprazole 40mg
Drug: AZD3355 · Drug: Esomeprazole
150 mg bid, oral, 7 days
Also known as: Lesogaberan
40 mg od, oral, 7 days
Also known as: Nexium
PK variables
Time frame: Frequent sampling occasions during day 7 each treatment period
4-BOH cholesterol
Time frame: Sampling occasions during day 7 one treatment period (AZD3355 alone)
Safety variables (adverse events, blood pressure, pulse, safety lab)
Time frame: During the whole treatment period
The record gives a start of Mar 2008, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lesogaberan · Esomeprazole